H.C. Wainwright Starts Lexicon Pharmaceuticals (LXRX) at Buy

H.C. Wainwright initiated coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Buy rating and a price target of $26.

Analyst Shaunak Deepak said, "Strong partnerships, positive pivotal data, and over $400M in cash at 2Q, put Lexicon in an enviable position going into 2017, in our opinion. We would be buyers of LXRX going into the December readout of the second inTandem2 pivotal trial for sotagliflozin in type 1 diabetes and the February FDA approval decision for telotristatethyl for carcinoid syndrome."

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $18.50 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
• TechnipFMC (FTI) PT Raised to $30 at BTIG